CytoMed Therapeutics Limited (GDTC)
NASDAQ: GDTC · IEX Real-Time Price · USD
2.100
-0.140 (-6.25%)
At close: Jul 19, 2024, 4:00 PM
2.040
-0.060 (-2.86%)
Pre-market: Jul 22, 2024, 7:47 AM EDT
CytoMed Therapeutics Employees
The last reported number of employees for CytoMed Therapeutics was 28.
Employees
28
Change
n/a
Growth
n/a
Revenue / Employee
n/a
Profits / Employee
-$111,821
Market Cap
24.24M
No historical employees data available.
Related Stocks
| Company Name | Employees |
|---|---|
| Meihua International Medical Technologies Co. | 617 |
| Trinity Biotech | 380 |
| Accelerate Diagnostics | 134 |
| Femasys | 34 |
| Unity Biotechnology | 19 |
| NeuroOne Medical Technologies | 16 |
| Akso Health Group | 12 |
| Cocrystal Pharma | 12 |
GDTC News
- 5 days ago - CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers - GlobeNewsWire
- 4 months ago - CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration - Accesswire
- 4 months ago - CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies - GlobeNewsWire
- 5 months ago - CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair - GlobeNewsWire
- 6 months ago - Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology - GlobeNewsWire
- 8 months ago - CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology - PRNewsWire
- 8 months ago - CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update - PRNewsWire
- 8 months ago - CytoMed Therapeutics to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference - PRNewsWire